



Société Anonyme à Conseil d'Administration
au capital de 21 610 998,20 euros
Siège social: 49 boulevard du Général Martial Valin, 75015 Paris
RCS 410 910 095 Paris

Press Release

Valerio Therapeutics' financial situation

As announced in February 2025, the decision was made to refocus the Company's activities to meet the challenge of financing the Company.

In the first few months of the year, the Company concentrated on two key priorities:

- Strengthening its financial position by restructuring debt and seeking new capital to support future development.
- Advancing its internal pipeline and pursuing partnerships built around its two core platforms: single -domain antibodies (V -body) and chemistry.

Following productive discussions with stakeholders, the Company has finalized an agreement to extend the maturity of its bank debt and to reduce or defer payments to its main suppliers. Negotiations with certain other creditors are still ongoing.

The Company's principal shareholders, Artal International Inc. and Financière de la Montagne, have provided advances totaling €5.5 million. These funds, part of which have already been used to settle debts, are expected to be converted into equity and will cover the Company's short-term needs, allowing operations to continue at least through the end of 2025. Nevertheless, the Company's financial position remains fragile, and securing a long-term, sustainable financing solution is a top priority.

"A major reorganization has been implemented since the management change in November 2024. Thanks to the support of our two main shareholders and the agreements reached with key creditors, we have successfully extended our cash runway through year-end. As previously announced, we have also reduced operating costs through workforce adjustments. The strategic reorientation initiated earlier this year has brought the Company back to its core in preclinical research. We are actively prioritizing our programs to unlock the full potential of our platforms," said Julien Miara.

The Company remains fully committed to securing long-term financing to support its strategic goals and will keep the market informed of future developments.

For more information, visit www.valeriotx.com.

CONTACTS

Valerio Therapeutics

Investor Relations:

ir@valeriotx.com | +33 (0) 1 70 38 33 99
